Ibrutinib can markedly increase CD4+ and CD8+ T cell numbers in CLL patients, most prominently in effector/effector memory subsets, leading to decreased Treg/CD4+ T cell ratios alongside alleviation of the tolerogenic and immunosuppressive skewing that is characteristic of CLL [75]. This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.